Key facts
- Immunis’s last known valuation is $75.0M.
- It has raised $37.0M across 2 recorded rounds; the latest was Early Stage VC ($12.0M) in May 2026.
- Notable investors include BOLD Capital Partners, Elevation Capital (Canada), Angel Star Ventures, Continuum Health Ventures, Fairfax Financial Holdings — 12 tracked in total.
- Immunis has filed 2 Form Ds with the SEC, most recently Oct 2024 ($20.4M sold to 27 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Immunis
Funding rounds
2 roundsAbout Immunis
Developer of stem cell-derived therapy designed to treat age and disease-related immune decline. The company's technology uses human stem cells for clinical use and directs them to become pure populations of defined cells that secrete factors, enabling doctors to treat patients with immune system development, modulation, and health.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2019
- Employees
- 19
- Website
- immunisbiomedical.com/
- Ownership
- Privately Held (backing)
Immunis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunis in its N-PORT filings yet. We sweep new filings monthly.